CNBX Stock - CNBX Pharmaceuticals Inc.
Unlock GoAI Insights for CNBX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | $130,074 | $410,165 | $29,958 | N/A |
| Gross Profit | N/A | $130,074 | $410,165 | $-169,000 | $-221,000 |
| Gross Margin | N/A | 100.0% | 100.0% | -564.1% | N/A |
| Operating Income | $-271,691 | $-583,000 | $-931,000 | $-2,954,000 | $-2,600,000 |
| Net Income | $-313,976 | $-695,000 | $-3,710,000 | $-3,723,000 | $-3,194,000 |
| Net Margin | N/A | -534.3% | -904.5% | -12427.4% | N/A |
| EPS | $-0.00 | $-0.02 | $-0.42 | $-3.59 | $-2.16 |
CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.
Visit WebsiteEarnings History & Surprises
CNBXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 13, 2026 | — | — | — | — |
Q1 2026 | Jan 12, 2026 | — | — | — | — |
Q3 2025 | Jul 14, 2025 | — | $-0.00 | — | — |
Q2 2025 | Apr 14, 2025 | — | $-0.00 | — | — |
Q1 2025 | Jan 10, 2025 | — | $-0.00 | — | — |
Q4 2024 | Nov 27, 2024 | — | $-0.00 | — | — |
Q3 2024 | Jul 15, 2024 | — | $-0.00 | — | — |
Q2 2024 | Apr 16, 2024 | — | $-0.01 | — | — |
Q1 2024 | Jan 12, 2024 | — | $-0.01 | — | — |
Q4 2023 | Nov 29, 2023 | — | $-0.03 | — | — |
Q3 2023 | Jul 14, 2023 | — | $-0.02 | — | — |
Q2 2023 | Apr 14, 2023 | — | $-1.34 | — | — |
Q1 2023 | Jan 13, 2023 | — | $-0.28 | — | — |
Q4 2022 | Nov 30, 2022 | — | $-0.39 | — | — |
Q3 2022 | Jul 14, 2022 | — | $-0.55 | — | — |
Q2 2022 | Apr 12, 2022 | — | $-1.42 | — | — |
Q1 2022 | Jan 13, 2022 | — | $-1.21 | — | — |
Q4 2021 | Nov 29, 2021 | — | $-0.56 | — | — |
Q3 2021 | Jul 14, 2021 | — | $-1.17 | — | — |
Q2 2021 | Apr 14, 2021 | — | $-0.47 | — | — |
Latest News
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
📈 Positive'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
📈 PositiveFrequently Asked Questions about CNBX
What is CNBX's current stock price?
What is the analyst price target for CNBX?
What sector is CNBX Pharmaceuticals Inc. in?
What is CNBX's market cap?
Does CNBX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CNBX for comparison